Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 9/20 | 0.73 |
| ▸ | CTSK | P43235 | 8/20 | 0.73 |
| ▸ | CTSB | P07858 | 3/20 | 0.63 |
| ▸ | CTSL | P07711 | 1/20 | 0.63 |
| ▸ | BCL2 | P10415 | 1/20 | 0.60 |
| ▸ | AKT1 | P31749 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | REN | P00797 | 2/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | CCKAR | P32238 | 1/20 | 0.50 |
| ▸ | CCKBR | P32239 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5556757 | 0.94 | CTSS (0.71) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL3004471 | 0.94 | CTSS (0.71) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL3004474 | 0.94 | CTSS (0.71) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL3698863 | 0.89 | CTSS (0.74) | CTSSCTSKCTSBCTSLBCL2 | |
| SCHEMBL3698861 | 0.89 | CTSS (0.74) | CTSSCTSKCTSBCTSLBCL2 | |
| SCHEMBL3826624 | 0.88 | CTSS (0.73) | CTSSCTSKCTSBCTSLBCL2 | |
| SCHEMBL24438783 | 0.87 | CTSS (0.69) | CTSSCTSKCTSBCTSLBCL2 | |
| SCHEMBL20415725 | 0.87 | CTSS (0.57) | CTSSCTSKCTSBCTSLBCL2 | |
| SCHEMBL13821431 | 0.87 | CTSS (0.69) | CTSSCTSKCTSBCTSLBCL2 | |
| SCHEMBL31633736 | 0.87 | CTSS (0.70) | CTSSCTSKCTSBCTSLBCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. | 2007-01-18 | — | — | US | disclosed |
| WO-2007005491-A1 | HYDRAZIDE CONJUGATES AS IMAGING AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | CA14, CA13, CA1 | CTSS 1532/4885CTSK 1070/4885CTSB 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.